Intervention

lorigerlimab

ClinicalTrials.gov intervention label

Clinical trials2

Recruiting0

Common conditions16

Lead sponsors shown1

Clinical trials

2 shown

A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate CancerNCT05848011 · 2023-09-28

A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid TumorsNCT05293496 · 2022-04-19

Common conditions

Advanced Solid Tumor1 Androgen-Independent Prostatic Cancer1 Androgen-Independent Prostatic Neoplasms1 Androgen-Insensitive Prostatic Cance1 Androgen-Resistant Prostatic Cancer1 Castration-Resistant Prostatic Cancer1 Epithelial Ovarian Cancer1 Hepatocellular Cancer1 Hormone Refractory Prostatic Cancer1 Immune Checkpoint Inhibitor1 Immunotherapy1 Inhibitory Checkpoint Molecule1 Malignant Melanoma1 Pancreatic Ductal Carcinoma1 Prostate Cancer Recurrent1 Renal Cell Carcinoma1

Leading sponsors

Trial status mix

COMPLETED2

Phase mix

PHASE11

PHASE21

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.